Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 6/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27751845 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP2C9CYP2C19HIF1ACHRM1 | |
| SCHEMBL4978863 | 0.98 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP2C9CYP2C19HIF1ACHRM1 | |
| SCHEMBL5967364 | 0.90 | CHRM1 (0.46) | SMN1; SMN2CYP2C9CYP2C19HIF1ACHRM1 | |
| SCHEMBL435610 | 0.89 | CYP2C9 (0.45) | SMN1; SMN2CYP2C9CYP2C19HIF1AEPHX1 | |
| Valeric Acid SCHEMBL27540568 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP2C9CYP2C19HIF1ATDP1 | |
| SCHEMBL1032475 | 0.87 | LCK (0.47) | SMN1; SMN2CYP2C9CYP2C19HIF1AEPHX1 | |
| SCHEMBL407615 | 0.86 | CA2 (0.44) | SMN1; SMN2CYP2C9CYP2C19HIF1ACPN1 | |
| SCHEMBL1527354 | 0.86 | CA2 (0.44) | SMN1; SMN2CYP2C9CYP2C19HIF1ACPN1 | |
| SCHEMBL2555276 | 0.85 | LCK (0.50) | CYP2C9CYP2C19HIF1AEPHX1 | |
| SCHEMBL10494941 | 0.85 | LCK (0.50) | CYP2C9CYP2C19HIF1AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116731698-B | Multi-effect nano emulsion and preparation method, using method and application thereof | 中海油田服务股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-116731698-A | Multi-effect nano emulsion and preparation method, using method and application thereof | 中海油田服务股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-102245564-A | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE INC | 2011-11-16 | — | — | CN | claimed |
| WO-2006105842-A1 | SYNERGISTS FOR BOOSTING THE ACTION OF REPELLENTS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | claimed |
| CN-1200703-C | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2005-05-11 | — | — | CN | claimed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| CN-1322524-A | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2001-11-21 | — | — | CN | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| CN-1054872-C | Aqueous anti-corrosion treating agent and its preparing and using method | UNIV DONGBEI (CN) | 2000-07-26 | — | — | CN | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| CN-1113927-A | Aqueous anti-corrosion treating agent and its preparing and using method | UNIV DONGBEI (CN) | 1995-12-27 | — | — | CN | claimed |
| CN-1100408-A | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-03-22 | — | — | CN | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| CN-116731698-B | Multi-effect nano emulsion and preparation method, using method and application thereof | 中海油田服务股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-111465849-B | Quantitative method for determining organic acid content of crude oil | 英国石油勘探运作有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-87100308-A | Polypeptide compound | — | 1987-09-16 | — | — | CN | disclosed |
| EP-0231077-A2 | Polypeptide compounds | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-05 | — | — | EP | disclosed |
| US-4243655-A | CONTAINING BIOTIN ANTAGONISTS | GUNTHER ROLAND E | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | SMN1; SMN2 373/4885CYP2C9 581/4885CYP2C19 1586/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | SMN1; SMN2 138/4885CYP2C9 1926/4885CYP2C19 3633/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | SMN1; SMN2 3657/4885CYP2C9 4616/4885CYP2C19 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.